TY - JOUR
KW - adverse effects
KW - Bunavail
KW - buprenorphine
KW - buprenorphine/naloxone
KW - Catapres
KW - clonidine
KW - Clonidine/administration & dosage/adverse effects/analogs & derivatives/therapeutic use
KW - Dolophine
KW - Dosage
KW - Drug Approval
KW - Drug Interactions
KW - Efficacy
KW - Humans
KW - Indivor
KW - lofexidine
KW - Lucemyra
KW - Metadol
KW - Methadone
KW - naloxone
KW - Narcotic Antagonists/administration & dosage/adverse effects/therapeutic use
KW - opioid dependence
KW - Opioid-Related Disorders/drug therapy
KW - Opioids
KW - Pregnancy
KW - Randomized Controlled Trials as Topic
KW - Safety
KW - Suboxone
KW - Substance Withdrawal Syndrome/drug therapy
KW - United States
KW - United States Food and Drug Administration
KW - Zubsolv
BT - The Medical letter on drugs and therapeutics
C5 - Opioids & Substance Use
CP - 1551
CY - United States
IS - 1551
JF - The Medical letter on drugs and therapeutics
PP - United States
PY - 2018
SN - 1523-2859; 0025-732X
SP - 115
EP - 117
EP - 
T1 - Lofexidine (Lucemyra) for opioid withdrawal
T2 - The Medical letter on drugs and therapeutics
TI - Lofexidine (Lucemyra) for opioid withdrawal
U1 - Opioids & Substance Use
U2 - 30036346
VL - 60
VO - 1523-2859; 0025-732X
Y1 - 2018
ER -